FDA panel rejects Merck’s Arcoxia

Share this article:
An FDA advisory panel voted against the approval of Merck’s Vioxx-successor Arcoxia (etoricoxib) as a treatment for osteoarthritis. The nonbinding vote on the drug was 20-1. The FDA is not required to follow the recommendations of its advisory panels, but usually does. Merck said it expects the FDA will make a final decision on Arcoxia by the end of the month. During a conference call with reporters after the Arcoxia vote, Robert Meyer, director of CDER's Office of Evaluation II, said that the committee was particularly concerned about the cardiovascular safety of the drug. Such risk concerns, he added, could mean that future NSAID or coxib agents could have to show a unique benefit to gain marketing approval. “It seems like [the committee] had concerns that, if there was just another product with the same level of risks of those out there now but no unique benefit, that...didn’t seem to be sufficient reason to approve such a product,” he said.
Share this article:
close

Next Article in News

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union